



Republic of the Philippines  
**DEPARTMENT OF HEALTH**  
**CENTER FOR HEALTH DEVELOPMENT**  
 Cordillera Administrative Region  
 Baguio City



**BAC Resolution No. 2020-91**  
**IB 2020-13 (REGULAR)**

**Package III - PROCUREMENT OF CONTRACEPTIVES (INJECTABLE AND IMPLANT)**

**RECOMMENDING THE AWARD OF CONTRACT FOR Item No. 1, and DECLARING FAILURE OF BIDDING for Item No. 2 FOR THE PROCUREMENT CONTRACEPTIVES (INJECTABLE AND IMPLANT) (Package III) for CY 2020 REQUIREMENTS**

**WHEREAS**, Open Competitive Bidding for the Procurement of Contraceptives (Injectable and Implant) (Package III) for CY 2020 requirements was conducted in accordance with the Republic Act 9184 (RA 9184) and its Revised Implementing Rules and Regulations;

**WHEREAS**, on August 15, 2020, the Invitation to Bid (IB) was posted in the PhilGEPS;

**WHEREAS**, a Pre-bidding Conference was held on August 25, 2020 at 10:00 am at DOH-CAR Office Regional Training Center, BGHMC Compound, Baguio City where six (6) prospective bidders attended, namely:

1. Ms. Rose B. Parel – Allied Hospital Supply
2. Mr. JC Balagot – Allied Hospital Supply
3. Ms. Jhessa Deo – Panamed Phils., Inc.
4. Ms. Jerlie Rafael – Phil Pharmawealth Inc.
5. Ms. Desiree V. Gorospe – Steritex Medical System
6. Ms. Evangeline Osalvo – Quinta Medical Healthcare Inc.

**WHEREAS**, the Submission and Opening of Bids took place as scheduled on September 07, 2020 at 10:00 am at the Regional Training Center, Department of the Health-Center for Health Development-Cordillera Administrative Region (DOH-CHD-CAR) Office, BGHMC Compound, Baguio City;

**WHEREAS**, two (2) prospective bidders procured the bidding documents and submitted their respective proposal, namely:

1. Phil Pharmawealth Inc.
2. SGS Healthcare Corp.

**WHEREAS**, the first envelopes containing the Eligibility and Technical Documents were opened. The presence, completeness and correctness of the required documents were checked and verified by the designated Bids and Awards Committee (BAC). Upon checking, Phil Pharmawealth Inc., and SGS Healthcare Corp. were declared “ELIGIBLE” and were rated “PASSED”;

**WHEREAS**, the second envelopes containing the Financial Proposal were opened. The presence, completeness and correctness of the required documents were checked and verified by the BAC. Upon checking, Phil Pharmawealth Inc., and SGS Healthcare Corp. were declared “ELIGIBLE”, were rated “PASSED” and subsequently the bid proposals were read publicly and written in the Abstract of Bids, to wit:

IB 2020-13 Procurement of Contraceptives (Injectable and Implant) (Package III)						Phil Pharmawealth Inc.	SGS Healthcare Copr.
Name of Company							
Bid Security Form						BSD	BSD
Amount of Security						N/A	N/A
Item No.	Item/Specification	Total Qty.	Unit	ABC per Unit	Total ABC		
1	MEDROXYPROGESTERONE ACETATE (MPA) Medroxyprogesterone Acetate (MPA) Injection (IM); 150 mg/ml, 1 ml vial injectable (IM) as acetate; Shelf life: must have thirty-six (36) months upon manufacture and 18 months upon delivery; standard	41,445	set	50.00	2,072,250.00	2,051,113.05 Offer: 500mg/ml, 3ml (PROVESTIN); 3ml auto disable syringe	2,061,888.75

	packaging of the manufacturer as approved by PFDA. Additional Support: 41,445 pieces of auto disable syringe 1ml, with 22G x 1 inch long needle 0.7 x 25 mm						
2	PROGESTIN SUBDERMAL IMPLANT (PSI) Etonogestrel, 68mg subdermal implant; Shelf life: total shelf life of sixty (60) months from the date of manufacture but not less than forty-two (42) months from the date of delivery. Primary Packaging: Each box contains 1 unit of single-rod contraceptive implant preloaded in a sterile disposable applicator, 1 patient card, 1 physician card and product info sheet. Secondary Packaging: Standard packaging of the manufacturer as approved by PFDA including product insert or encryption/imprint inside the box.	2,420	piece	700.00	1,694,000.00	NO BID	NO BID

WHEREAS, the bids for the item listed below was found to be substantially complying;

**Item No. 1 - MEDROXYPROGESTERONE ACETATE (MPA), Medroxyprogesterone Acetate (MPA) Injection (IM); 150 mg/ml, 1 ml vial injectable (IM) as acetate; Shelf life: must have thirty-six (36) months upon manufacture and 18 months upon delivery; standard packaging of the manufacturer as approved by PFDA.  
Additional Support: 41,445 pieces of auto disable syringe 1ml, with 22G x 1 inch long needle 0.7 x 25 mm**

Bidder No.	Name of Company	ABC (PhP)	Bid as Calculated	% Variance from ABC
1	Phil Pharmawealth Inc.	₱ 2,072,250.00	₱ 2,051,113.05	1.02 %
2	SGS Healthcare Corp.	₱ 2,072,250.00	₱ 2,061,888.75	0.50 %

WHEREAS, letter dated September 7, 2020 was sent to the Lowest Calculated Bidder (LCB), Phil Pharmawealth Inc., requesting to submit post qualification requirements;

WHEREAS, on September 11, 2020, Phil Pharmawealth Inc. submitted their respective additional documentary requirements as part of their technical requirements. Offer of Phil Pharmawealth Inc. is 50mg/3ml, hence disqualified and SGS Healthcare Corp. was requested to submit additional documentary requirements and post qualification requirements;

WHEREAS, on September 8-15, 2020, detailed evaluation of the submitted proposal on the Legal, Technical and Financial aspects of documents on the Lowest Calculated Bidder (LCB) for the above items was undertaken by the designated Technical Working Group (TWG);

WHEREAS, on September 22, 2020, the TWG presented to the BAC their Bid Evaluation and Post Qualification Reports citing specific findings on the submitted documents/clarifications by the LCB for each item;

WHEREAS, on September 25, 2020, the TWG submitted their Bid Evaluation and Post Qualification Reports citing specific findings on the submitted documents/clarifications by the LCB for each item;

WHEREAS, the Bids and Awards Committee (BAC) certifies that there is "no pending incident" as regard to the result of the post qualification evaluation for this particular project;

NOW THEREFORE, on the basis of the above, the herein members of the BAC HEREBY RESOLVE, to award the item listed below to the following bidder that was determined to have the Lowest Calculated and Responsive Bid (LCRB):

1. **SGS Healthcare Co. with a Total Contract Price of Two Million Sixty-One Thousand Eight Hundred Eighty-Eight Pesos and Seventy-Five Centavos only (₱ 2,061,888.75) inclusive of local taxes for the item listed below:**

Item No.	Description	Quantity	Unit	Unit Cost	Total Bid Price (PhP)
1	MEDROXYPROGESTERONE ACETATE (MPA)	41,445	set	₱ 49.75	₱ 2,061,888.75

Medroxyprogesterone Acetate (MPA) Injection (IM); 150 mg/ml, 1 ml vial injectable (IM) as acetate; Shelf life: must have thirty-six (36) months upon manufacture and 18 months upon delivery; standard packaging of the manufacturer as approved by PFDA. Additional Support: 41,445 pieces of auto disable syringe 1ml, with 22G x 1 inch long needle 0.7 x 25 mm				
<b>TOTAL</b>				<b>₱ 2,061,888.75</b>

WHEREAS, the following item was declared failed bid:

**NO BID**

**Item No. 2 - PROGESTIN SUBDERMAL IMPLANT (PSI)**, Etonogestrel, 68mg subdermal implant; Shelf life: total shelf life of sixty (60) months from the date of manufacture but not less than forty-two (42) months from the date of delivery.

Primary Packaging:

Each box contains 1 unit of single-rod contraceptive implant preloaded in a sterile disposable applicator, 1 patient card, 1 physician card and product info sheet.

Secondary Packaging:

Standard packaging of the manufacturer as approved by PFDA including product insert or encryption/imprint inside the box.

For the item declared as **“FAILED BID”**, specifically item number 2, the end-user is mandated to review the technical specifications and if necessary, adjust the ABC subject to the required approvals and for re-bidding with re-advertisement and/or posting, as prescribed in Section 21.2 of the Revised Implementing Rules and Regulations of the Republic Act No. 9184.

**UNANIMOUSLY APPROVED** this 28<sup>th</sup> day of September, 2020 at the Department of Health-Center for Health Development-Cordillera Administrative Region, BGHMC Compound, Baguio City.

**BIDS AND AWARDS COMMITTEE (BAC)**


  
ANACHRIS M. KILAKIL, MD, MPM  
Provisional Member

  
JENNIFER JOYCE R. PIRA, MD, MDM  
Provisional Member

  
ALEXEI P. MARRERO, MD  
BAC Member

  
SHELLY M. ARAL, MD, MCHD  
BAC Member

ATTY. VERONICA ZANDRA DE JESUS-SOWAKEN  
BAC Member

  
ARCELY D. SANCHEZ, MBA  
BAC Vice Chairperson

  
JANICE Z. BUGTONG, MD, MM, CESE  
BAC Chairperson

Approved by:

  
RUBY C. CONSTANTINO, MD, MPH, CESO IV  
OIC-Director IV